Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 12/20 | 0.60 |
| ▸ | ITGA2B | P08514 | 12/20 | 0.60 |
| ▸ | DRD2 | P14416 | 1/20 | 0.40 |
| ▸ | DRD1 | P21728 | 1/20 | 0.40 |
| ▸ | DRD4 | P21917 | 1/20 | 0.40 |
| ▸ | DRD5 | P21918 | 1/20 | 0.40 |
| ▸ | DRD3 | P35462 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL8540812 | 0.99 | ITGB3 (0.59) | ITGB3ITGA2BDRD2DRD1DRD4 | |
| SCHEMBL6951967 | 0.97 | ITGB3 (0.61) | ITGB3ITGA2BDRD2DRD1DRD4 | |
| SCHEMBL6958054 | 0.94 | ITGB3 (0.63) | ITGB3ITGA2BKMT2AMEN1 | |
| SCHEMBL6951257 | 0.91 | ITGB3 (0.65) | ITGB3ITGA2BKMT2AMEN1 | |
| Hydrochloric Acid SCHEMBL6948861 | 0.91 | ITGB3 (0.49) | ITGB3ITGA2BDRD2DRD1DRD4 | |
| Hydrochloric Acid SCHEMBL6957967 | 0.88 | ITGB3 (0.49) | ITGB3ITGA2BKDM4EMAPTKMT2A | |
| SCHEMBL6953125 | 0.87 | ITGB3 (0.67) | ITGB3ITGA2BKDM4EMAPTKMT2A | |
| SCHEMBL6953788 | 0.85 | ITGB3 (0.62) | ITGB3ITGA2BDRD2DRD1DRD4 | |
| Hydrochloric Acid SCHEMBL6950240 | 0.85 | ITGB3 (0.51) | ITGB3ITGA2BKDM4EMAPTKMT2A | |
| SCHEMBL8541201 | 0.84 | ITGB3 (0.63) | ITGB3ITGA2BKDM4EMAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030130342-A1 | Glycoprotein llb/llla antagonists | FISHER MATTHEW J (US) | 2003-07-10 | — | — | US | disclosed |
| EP-0804431-B9 | GLYCOPROTEIN IIb/IIIa ANTAGONISTS | LILLY CO ELI (US) | 2003-01-02 | — | — | EP | disclosed |
| US-6448269-B1 | SUCH AS 6-(N-(4-(AMINOIMINOMETHYL)BENZOYL)AMINO)-3,4-DIHYDRO-4,4-DIMETHYL-2H-1 -BENZOPYRAN-2-YL)ACETIC ACID; INHIBITING PLATELET AGGREGATION OR FIBRINOGEN BINDING OR PREVENTING THROMBOSIS | ELI LILLY AND COMPANY | 2002-09-10 | — | — | US | disclosed |
| EP-0804431-B1 | GLYCOPROTEIN IIb/IIIa ANTAGONISTS | LILLY CO ELI (US) | 2002-07-24 | — | — | EP | disclosed |
| US-6020362-A | ANTICOAGULANTS | ELI LILLY AND COMPANY (US) | 2000-02-01 | — | — | US | disclosed |
| EP-0804431-A4 | GLYCOPROTEIN IIb/IIIa ANTAGONISTS | LILLY CO ELI (US) | 1998-04-29 | — | — | EP | disclosed |
| US-5731324-A | Glycoprotein IIb/IIIa antagonists | ELI LILLY AND COMPANY (US) | 1998-03-24 | — | — | US | disclosed |
| EP-0804431-A1 | GLYCOPROTEIN IIb/IIIa ANTAGONISTS | ELI LILLY AND COMPANY (US) | 1997-11-05 | — | — | EP | disclosed |
| WO-1996022288-A1 | GLYCOPROTEIN IIb/IIIa ANTAGONISTS | ELI LILLY AND COMPANY (US) | 1996-07-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030130342-A1 | Glycoprotein llb/llla antagonists | SELL, SELPLG, LY96 | ITGB3 653/4885ITGA2B 294/4885DRD2 2168/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.